Insights

  • Date

  • Content Type

  • Reset

Blog

Biopharma’s Big Inflection Point: There’s never been a better time to innovate with next-generation medicine

11.10.21

By Christian Schneider

In all of the years I have been tracking and helping to drive biotech innovation, I can say...

Read More

Blog

How to create a smart integrated drug development plan including considerations for cell and gene therapies

29.06.21

By Dr. Diane Seimetz

An integrated drug development plan is a critical tool for the efficient and effective progression from the R&D...

Read More

Blog

Risk Management Plans for ATMPs

13.06.21

By Maria Schacker

ATMPs are a relatively novel class of medicinal products with anew and very unique set of potential risks...

Read More

Blog

Neutralizing Antibody Assay Development – a key consideration for immunogenicity packages

1.06.21

By Jennifer Sales

Neutralising Antibodies, or NAbs, are a subclass of Anti-Drug Antibodies that may be formed during an unwanted immunogenic...

Read More

Blog

Wake up the Sleeping Beauty – Transposons in gene therapy: How do they compare to other genome modifying tools?

4.05.21

By Ewa Janosz

Gene therapy is currently a quickly developing field. Except from commonly known viral vectors and genome-editing tools, also...

Read More

Blog

Requests for proposals – Get the best value when asking for services

26.04.21

By Timo Liebig

You need a service provider, but which one suits your needs best? Read here how to efficiently structure...

Read More

We are now Cencora PharmaLex 

PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

Know more